Epicrispr Biotechnologies (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- March 26, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $68,000,000
Company Info
- Founders
- Amber Salzman
- Company Description
- Epicrispr Biotechnologies is a biotechnology company pioneering gene-modulating therapies, leading with treatments for neuromuscular diseases. The company's proprietary Gene Expression Modulation System (GEMS) enables precise, durable control of gene expression, unlocking first-in-class treatments for previously untreatable conditions.
- Market
- Gene-modulating therapies for neuromuscular diseases
- Location
- South San Francisco, California, USA
- Coinvestors
- Ally Bridge Group